PTK2 and glioblastoma: Based on the new role of FAK in modulating GBM stem cell energetics, we suggest that a combination of agents targeting FAK together with those that inhibit residual metabolic pathways in susceptible GBM subtypes may lead to enhanced therapeutic benefit.